Focused on providing early, non-invasive, and accurate prenatal diagnostic tests for fetal health
Employees: 201-500
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Illumina V... | illuminaVe... |
Mentions in press and media 5
| Date | Title | Description |
| 02.07.2015 | Five things you need to know about prenatal testmaker Natera’s $175M IPO | The company’s revenues grew from $55.2 million in 2013 to $159.3 million in 2014 — quite the increase. This comes largely from sales of the Panorama test – in the first three months of 2015 alone, it sold more than 55,000 of these tests. Th... |
| 13.01.2015 | The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped) | “It’s just that sequencing isn’t good enough today for many of the applications we’re looking at for future clinical use,” he said. Stuelpnagel, who now chairs Ariosa Diagnostics, 10X Genomics and the just-acquired Sequenta, spoke this week... |
| 26.03.2014 | Ariosa, maker of a genetic test for pregnant women, files for a $69M IPO | Ariosa Diagnostics is already a favorite with pregnant women. But it’s about to become a big name on Wall Street, too, with its initial public offering. Ariosa plans to offer $69 million in a proposed maximum aggregate offering price, but i... |
| - | The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped) | John Stuelpnagel – one of Illumina‘s cofounders – has never had his genome sequenced. “I didn’t feel the need,” Stuelpnagel said. It’s not because of the cost, nor the fear he’s got some genetic disorder. It’s not even because he believes i... |
| - | Five things you need to know about prenatal testmaker Natera’s $175M IPO | California genetic testmaker Natera just upped its IPO target from $100 million to $175 million and begins trading today, opening at $18 per share. Its ticker symbol on the Nasdaq is “NTRA.” The company’s lead product is its Panorama test. ... |